Plus Therapeutics, Inc. (PSTV)

Compare

1.0200

+0.0699

+(7.36%)

At close: 4:00:01 PM EDT

1.0299

+0.01

+(0.97%)

After hours: 4:46:19 PM EDT

Plus (PSTV) Upgraded to Buy: Here's What You Should Know

Plus (PSTV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 4 hours ago

PSTV
+7.36%
Q4 2024 Plus Therapeutics Inc Earnings Call

Q4 2024 Plus Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 4 days ago

PSTV
+7.36%
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

Plus Therapeutics Inc (PSTV) reports promising clinical progress and strategic funding, despite financial hurdles in its latest earnings call.

GuruFocus.com 4 days ago

PSTV
+7.36%
Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates

Plus (PSTV) delivered earnings and revenue surprises of -31.37% and 6.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 days ago

PSTV
+7.36%
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

The recent $15 million financing accelerates development of REYOBIQ™ and launch of CNSide™HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business h

GlobeNewswire 5 days ago

PSTV
+7.36%
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug

The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.

Zacks 11 days ago

PSTV
+7.36%
Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?

We recently published a list of 10 Micro-, Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Plus Therapeutics Inc. (NASDAQ:PSTV) stands against other micro-, small-cap firms that dominate Thursday’s gains. The stock market edged lower on Thursday, erasing gains from the previous trading day that was […]

Insider Monkey 11 days ago

PSTV
+7.36%
^GSPC
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Comp

GlobeNewswire 12 days ago

PSTV
+7.36%
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to

GlobeNewswire 13 days ago

PSTV
+7.36%
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous ...

ACCESS Newswire 21 days ago

PSTV
+7.36%
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq’s minimum stockholders’ equity requirement. The Company’s common stock will continue to be

GlobeNewswire 22 days ago

PSTV
+7.36%
Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday

We recently published an article titled Micro-, Small-Cap Firms Dominate Market Rally. In this article, we are going to take a look at where Plus Therapeutics, Inc. (NASDAQ:PSTV) stands against the other stocks. The stock market pulled back to the red territory on Thursday, with all major indices posting significant losses as tariff threats continued to […]

Insider Monkey 25 days ago

PSTV
+7.36%
^GSPC
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy

The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.

Zacks 25 days ago

PSTV
+7.36%
FDA ODD given to Plus Therapeutics’ injectable radiotherapy

The award of ODD status follows the completion of the single-dose Phase I ReSPECT-LM trial.

Pharmaceutical Technology 25 days ago

PSTV
+7.36%
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall survival of 17 months, more than double the 8-month median overall survival with standard of care HOUSTON, March 07, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced plat

GlobeNewswire 25 days ago

PSTV
+7.36%
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

HOUSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer. “Receivi

GlobeNewswire 26 days ago

PSTV
+7.36%
Plus Therapeutics Announces New Employment Inducement Grants

HOUSTON, March 05, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on February 28, 2025, it granted option awards to Dr. Michael Rosol, the Company’s new Chief Development Officer. The Company agreed to grant these equity awards to Dr. Rosol to induce him to commence employment w

GlobeNewswire 26 days ago

PSTV
+7.36%
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. “This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer thera

GlobeNewswire 28 days ago

PSTV
+7.36%
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 0% and 3.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

TBPH

PSTV
+7.36%
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

ReSPECT- LM Phase 1 single dose is now complete, and the recommended Phase 2 dose (RP2D) for single administration therapy has been determinedAUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the completion of the ReSPECT-LM Phase 1 single-dose escal

GlobeNewswire last month

PSTV
+7.36%

Performance Overview

Return	PSTV	S&P 500 (^GSPC)
YTD	-11.30%	-4.23%
1-Year	-43.33%	+7.42%
3-Year	-93.20%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Plus Therapeutics, Inc. (PSTV)

Plus (PSTV) Upgraded to Buy: Here's What You Should Know

Q4 2024 Plus Therapeutics Inc Earnings Call

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug

Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday

PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy

FDA ODD given to Plus Therapeutics’ injectable radiotherapy

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Performance Overview